Table 3. Five- and 10-Year Distant Metastasis-Free Survival Rates.
| ADT duration | % (95% CI) unadjusted | % (95% CI) adjusteda | ||||||
|---|---|---|---|---|---|---|---|---|
| 5 y | 10 y | 5 y | 10 y | |||||
| EBRT | EBRT+BT | EBRT | EBRT+BT | EBRT | EBRT+BT | EBRT | EBRT+BT | |
| Distant metastasis-free survival | ||||||||
| Retrospective data set | ||||||||
| 4-8 mo | 79.3 (73.4-85.1) | 89.4 (85.3-93.4) | 49.7 (40.5-58.9) | 61.5 (53.6-69.4) | 75.4 (68.9-81.9) | 89.6 (85.5-93.8) | 47.4 (38.2-56.6) | 60.9 (53-68.8) |
| 14-20 mo | 81.5 (70.9-92.1) | 92.9 (88.4-97.4) | 50.6 (27.3-73.9) | 73.7 (63.4-84.1) | 79 (63.8-94.1) | 95.4 (88.1-100.0) | 37.9 (7.1-68.8) | 73.2 (53.9-92.5) |
| RADAR | ||||||||
| 6 mo | 78.8 (70.1-87.5) | 73.2 (64.5-81.8) | 61 (50.6-71.4) | 57 (47.2-66.7) | 79.6 (70.8-88.3) | 72 (63.2-80.8) | 61 (50.4-71.6) | 55.4 (45.6-65.2) |
| 18 mo | 77.8 (69.4-86.2) | 84.3 (77.3-91.4) | 60.4 (50.5-70.3) | 68.6 (59.6-77.6) | 76.7 (68.1-85.3) | 84.7 (77.6-91.7) | 59.6 (49.5-69.6) | 69.8 (60.8-78.8) |
| DART 28 mob | 93.5 (87.9-99.1) | NA | NA | NA | 93.5 (87.9-99.1) | NA | NA | NA |
| Overall survival | ||||||||
| Retrospective data set | ||||||||
| 4-8 mo | 84.9 (79.8-90.1) | 90.6 (86.8-94.5) | 57.2 (47.8-66.6) | 66.5 (58.8-74.2) | 83.8 (78-89.6) | 91 (87.1-94.9) | 57.5 (47.9-67) | 65.9 (58.1-73.7) |
| 14-20 mo | 90.2 (81.9-98.5) | 95.3 (91.6-99) | 55 (29-81.1) | 76.1 (66-86.3) | 87.4 (74.8-99.9) | 97 (91-100.0) | 39.5 (7-72) | 75.2 (56.4-94) |
| RADAR | ||||||||
| 6 mo | 90.6 (84.4-96.8) | 90 (84.2-95.9) | 69.3 (59.5-79.2) | 72.9 (64.1-81.6) | 90.6 (84.2-96.9) | 89.1 (83-95.3) | 68.5 (58.4-78.5) | 71.5 (62.6-80.4) |
| 18 mo | 88.4 (81.9-94.8) | 95.1 (90.9-99.3) | 69 (59.6-78.4) | 78.4 (70.4-86.4) | 87.3 (80.5-94) | 94.8 (90.5-99.2) | 68.2 (58.7-77.8) | 79.5 (71.6-87.5) |
| DART 28 mo | 96 (91.5-100) | NA | NA | NA | 96 (91.5-100) | NA | NA | NA |
Abbreviations: ADT, androgen deprivation therapy; DART, Deprivación Androgénica y Radio Terapía (Androgen Deprivation and Radiation Therapy) 01/05 trial; EBRT, external beam radiotherapy; EBRT+BT, external beam radiotherapy plus brachytherapy boost; NA, not applicable; PSA, prostate-specific antigen; RADAR, the Randomized Androgen Deprivation and Radiotherapy 03/04 trial.
a
Adjustments made using an inverse probability of treatment weighting approach, wherein propensity scores included treatment type (if relevant), ln(initial PSA), clinical T category, Gleason grade group, and age (y) at treatment as independent covariates.
b
The median follow-up period for the DART was only 5.3 years; thus, 10-year estimates are not provided.